Publication Name	World Journal of Pharmacology
Manuscript ID	69374
Country	United States

Received	2021-06-28 14:14
Peer-Review Started	2021-06-28 14:17
To Make the First Decision
Return for Revision	2021-07-31 04:36
Revised	2021-08-22 19:02
Second Decision	2021-09-14 03:39
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-09-17 02:44
Articles in Press	2021-09-17 02:44
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-10-21 17:40
Typeset the Manuscript	2021-11-15 06:30
Publish the Manuscript Online	2021-11-17 12:02

ISSN	2220-3192 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Review
Article Title	Therapeutics for treatment of SARS-CoV2 (COVID-19): A safety perspective
Manuscript Source	Unsolicited Manuscript
All Author List	Joshua Davis, Ugochukwu Umeh and Rand Saba
Funding Agency and Grant Number
Corresponding Author	Joshua Davis, MD, Attending Doctor, Department of Emergency Medicine, Vituity, 929 N. St. Francis Avenue, Wichita, KS 67214, United States. jjvwd@udel.edu
Key Words	COVID-19; Coronavirus; SARS-CoV2; SARS; Drug safety; Pharmacotherapy
Core Tip	The novel coronavirus disease 2019 (COVID-19) has radically changed the approach to healthcare and public health in the last year. Over 100 million people worldwide have been affected. Dexamethasone appears to be the most efficacious drug for appropriately selected patients with COVID-19 (i.e., those requiring supplemental oxygen). Remdesivir may reduce length of hospitalization with mild side effects. While they do not have enough evidence to be recommended at this time, ivermectin and zinc should be studied further for early illness and interferon and interleukin blockade should be studied for critical illness. Hydroxychloroquine/chloroquine, azithromycin, and vitamins C and D have no evidence of benefit at this time.
Publish Date	2021-11-17 12:02
Citation	Davis J, Umeh U, Saba R. Therapeutics for Treatment of SARS-CoV2 (COVID-19): A Safety Perspective. World J Pharmacol 2021; 10(1) 1-32
URL	https://www.wjgnet.com/2220-3192/full/v10/i1/1.htm
DOI	https://dx.doi.org/10.5497/wjp.v10.i1.1

Full Article (PDF)	WJP-10-1.pdf
Full Article (Word)	WJP-10-1.docx
Manuscript File	69374_Auto_Edited_Kerr C_Clear Copy.docx
Answering Reviewers	69374-Answering reviewers.pdf
Audio Core Tip	69374-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	69374-Conflict-of-interest statement.pdf
Copyright License Agreement	69374-Copyright license agreement.pdf
Supplementary Material	69374-Supplementary material.pdf
Peer-review Report	69374-Peer-review(s).pdf
Scientific Misconduct Check	69374-Bing-Wang JL-1.jpg
Scientific Misconduct Check	69374-Bing-Liu M-2.png
Scientific Editor Work List	69374-Scientific editor work list.pdf